Treon, Steven P., MD, PhD – Dana-Farber Cancer Institute, Boston, MA (Project Period 6/1/2013 to 5/31/2015).
TITLE: “Development of Targeted Therapies for Waldenstrom’s Macroglobulinemia.”
[A continuation of a previous project proposed by Dr. Treon and partially funded by the IWMF. This current study proposes to define the oncogenic signaling of MYD88 L265P in WM, to identify and validate inhibitors of MYD88-directed signaling in WM, and to characterize MYD88 pathway inhibitors in vivo and initiate early clinical phase studies in WM patients.]
Carrasco, Ruben, MD, PhD – Dana-Farber Cancer Institute, Boston, MA (Project Period 12/1/2012 to 11/30/2015).
Waldenstrom’s Macroglobulinemia Foundation of Canada portion of funding $112,500, Leukemia & Lymphoma Society portion of funding $112,500.
TITLE: “Development of a Mouse Genetic Model of Waldenstrom Macroglobulinemia.”
[A study jointly funded by the Leukemia & Lymphoma Society and Waldenstrom’s Macroglobulinemia Foundation of Canada (an IWMF affiliate) to generate a mouse model of the disease that recapitulates its clinicopathologic features by engineering the MYD88 L265P mutation in the mice. These mice will be evaluated for LPL/WM involvement over time as well as biochemical and functional characterization of transgenic B-cells to define the role of MYD88 L265P mutation in oncogenesis.]
Azab, Abdel Kareem, PhD – Washington University, St. Louis, MO (Project Period 7/01/12-6/30/14).
TITLE: “The Role of Hypoxia in the Dissemination of Waldenström Macroglobulinemia.”
[A study to determine the role of hypoxia in WM cell dissemination in vivo, to characterize molecular changes regulated by hypoxia in WM cells in vitro, and to determine the role of a signaling pathway called Hypoxia Inducible Factor (HIF) in WM cell response to hypoxia and the effect of HIF inhibitors on the progression of WM in vitro and in vivo.]
Ansell, Stephen M., MD, PhD – Mayo Clinic, Rochester, MN (Project Period 11/01/11-10/31/14).
TITLE: “Factors Regulating Immunoglobulin-Producing B-Cells in Patients with Waldenstrom’s Macroglobulinemia.”
[A continuation of previous projects proposed by Dr. Ansell and funded by the IWMF. This current study proposes to characterize the expression and activation of STAT5A and STAT5B in WM cell lines and patient-derived tumor cells, to determine the individual influence of STAT5A and STAT5B on the subsequent expression of downstream targets in WM, and to evaluate the effects of isoform-specific STAT5 inhibition on the biology of the WM tumor.]
Ghobrial, Irene, MD – Dana-Farber Cancer Institute, Boston, MA (Project Period 9/01/10-8/31/14).
TITLE: “Large Scale Genomic and Proteomic Profiling in Waldenstrom’s Macroglobulinemia.”
[A study to develop a tissue bank of WM specimens linked to clinical characteristics of patients in different stages of the disease, to characterize the genetics and proteomics of WM cells during disease progression, and to develop biomarkers that evaluate in vivo activity of therapeutic agents in WM patients treated in clinical trials.]
To participate in IWMF's Tissue Bank Project,click here.